An Exploratory Study of BPS804 Treatment in Adult Patients With Type I, III or IV Osteogenesis Imperfecta

Withdrawn before enrolling · Phase 2

Conditions studied: Osteogenesis Imperfecta

In brief

The purpose of this study is to investigate the effect of BPS804 on strength/quality of bone in patients with Type I, III or IV Osteogenesis imperfecta using a special type of CT scanner. Participants will be treated for 1 year.

Key facts

Study ID

NCT03216486

Run by

Ultragenyx Pharmaceutical Inc

People needed

0

Starts

2017-10-31

Expected to finish

2018-11-01

Last updated by the study team

2023-07-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with a clinical diagnosis of OI Type I, III or IV
• Capable of giving signed consent

You may not qualify if…

• History of skeletal malignancies or other bone diseases (other than OI)
• History of endocrine or thyroid/parathyroid conditions that could affect bone metabolism
• Treatment with bisphosphonates within 3 months of randomisation
• Treatment with teraparatide, denosomab or other anabolic/antiresorbative medications within 6 months of randomisation

Where it is running

• Mereo Investigator Site — Albuquerque, New Mexico, United States
• Mereo Investigator Site — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.